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bjectives The aim of this study was to investigate physiological and clinical consequences of per-
utaneous pulmonary valve implantation (PPVI) in patients with chronic right ventricular outﬂow
ract (RVOT) obstruction and volume overload.
ackground The PPVI is a nonsurgical technique to address RVOT conduit dysfunction.
ethods Twenty-eight adolescents (median age 14.9 years; age range 10.9 to 19 years) underwent
PVI due to RVOT stenosis and/or pulmonary regurgitation (PR). Before and after PPVI echocardio-
raphic and magnetic resonance imaging, cardiopulmonary exercise tests were obtained.
esults The RVOT gradient (p  0.001) and right ventricular (RV) systolic pressure decreased (p 
.001), acutely. Magnetic resonance imaging (median 6 months) documented reduction in RV end-
iastolic (149  49 ml/m2 vs. 114  35 ml/m2, p  0.005) volume, increases in left ventricular (LV)
nd-diastolic (p  0.007) volume and cardiac output (RV: p  0.04 and LV: p  0.02), and reduced
R fraction (24  10% to 7  7%, p  0.0001). Symptoms, aerobic exercise performance (maximal
xygen consumption: p  0.0001) and ventilatory response to carbon dioxide production (p 
.003) improved. After 24 months, echocardiography demonstrated the RV/systemic-pressure ratio,
nd RVOT peak pressure gradient reductions persisted, and PR was absent in 93% (n  12 of 13) of
he cohort. Freedom from surgery was 91%, 83%, and 83%, and freedom from transcatheter reinter-
ention was 91%, 80%, and 80%, at 12, 24, and 36 months, respectively. There were no acute
evice-related complications, with stent fractures noted in 10.8%.
onclusions Percutaneous pulmonary valve implantation is feasible and safe in the young with
ysfunctional RVOT conduits. An improvement in symptoms, hemodynamic status, and objective
ndings of exercise performance occurs. Early follow-up demonstrates persistent improvement in
entricular parameters, PR, and objective exercise capacity. (J Am Coll Cardiol Intv 2010;3:439–48)
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440econstruction of the right ventricular outflow tract
RVOT) with a conduit or bioprosthetic valve is often
equired in strategies applied to children with complex heart
isorders (1–3). As such, the longevity of the RVOT
econstruction is limited (4–6), with pulmonary regurgita-
ion (PR) identified as a risk factor for long-term morbidity
nd mortality (7–9) and the primary indication for reopera-
ion (9,10). Although surgical outflow tract revision is
ssociated with a low morbidity and mortality (7,11), such
eplacements have a limited life span and require additional
pen heart procedures. The potential for an effective per-
utaneous implantation of a pulmonary valve to address
bstructive and/or regurgitant lesions would have a signifi-
ant impact on developing treatment algorithms.
In this regard, percutaneous pulmonary valve implanta-
tion (PPVI) was introduced by
Bonhoeffer et al. (12) as a non-
surgical treatment of RVOT
dysfunction, with the largest re-
ported experience in 155 pa-
tients implanted at a median age
of 21 years (13). Implantation
was technically successful with a
low complication rate and
marked improvement in right
ventricular (RV) hemodynamic
status (13). In this study, de-
scribed are the acute results and
clinical outcomes of PPVI in a
unique childhood population
with dilated RVs and early-term
follow-up.
Methods
Patients. Between October 2005
and December 2008, 28 adoles-
cents underwent PPVI at the
Hospital for Sick Children, To-
onto, Canada. Written consent was obtained from older
hildren and/or the parents as appropriate. Ethics committee
pproval was obtained for this review, and consent was waived
s to the retrospective nature of the study. Inclusion and
xclusion criteria are outlined in Table 1.
ssessment of RV function, outﬂow gradient, and PR. The
V functional status and degree of dilation were assessed
n all, with a Philips IE-33 (Andover, Massachusetts)
-dimensional transthoracic echocardiographic system. The
VOT gradient was calculated from velocity flow, and the
egree of PR was determined qualitatively by color-flow
oppler. The PR was categorized as none  0; trivial  1
width of the regurgitant color jet 1/3 the diameter of the
ulmonary valve annulus); mild  2 (width of the regurgi-
bbreviations
nd Acronyms
F  ejection fraction
V  left ventricle/
entricular
VEDV  left ventricular
nd-diastolic volume
RI  magnetic resonance
maging
PVI  percutaneous
ulmonary valve implantation
R  pulmonary
egurgitation
V  right ventricle/
entricular
VEDV  right ventricular
nd-diastolic volume
VOT  right ventricular
utflow tract
E/VCO2  ventilatory
esponse to carbon dioxide
roductionant color jet 1/3 but1/2 the diameter of the pulmonary salve annulus); moderate 3 (width of the regurgitant color
et 1/2 but  the diameter of the pulmonary valve
nnulus); and severe  4 (width of the regurgitant color jet
qual to the diameter of the pulmonary valve annulus with
ow reversal in the branch pulmonary arteries). Grade 3
egurgitation or greater was considered significant. An
stimate of RV pressure was determined from the tricuspid
egurgitant jet velocity plus 5 mm Hg and compared to a
imultaneously obtained arm cuff blood pressure. Right
entricular end-diastolic dimensions were obtained from the
ong-axis parasternal view from the M-mode images. Tri-
uspid valve annulus diameter was measured in apical
-chamber view and a z-score assigned from our institu-
ional normative data.
The outflow tracts were classified as primarily stenotic
peak gradient 40 mm Hg); regurgitant (peak gradient
40 mm Hg and regurgitation grade 3); or mixed
stenosis with peak gradient 40 mm Hg and regurgitation
rade 3) (Fig. 1), from the echocardiographic studies.
etabolic exercise testing. Exercise testing was performed
n a programmable ergometer (Ergometrics-800S, Ergo-
ine, Bitz, Germany) with a ramp protocol, with respiratory
ata collected and analyzed breath-to-breath and averaged
ver 20 s with a metabolic cart (Max-1, Physio-Dyne
nstrument Corporation, Quogue, New York).
agnetic resonance imaging (MRI). Cardiac MRI was per-
ormed with a 1.5-T magnet (Siemens Avanto, Erlangen,
ermany, or CV/i, GE Healthcare, Milwaukee, Wiscon-
Table 1. Patient Selection Criteria
Inclusion
Clinical criteria
RV systolic pressure 2/3 systemic with clinical symptoms or
RV systolic pressure 3/4 of systemic with no clinical symptoms and/or
Moderate to severe PI and 1 of the following
Symptoms
Severe RV dysfunction
Severe RV dilation
Decreased exercise capacity (peak VO2max 65% predicted for normal)
Arrhythmias
Morphological criteria
RVOT dimensions 22  22 mm
RVOT dimensions 14  14 mm (by sizing balloon)
Weight 20 kg
Exclusion
Age 5 yrs or weight 20 kg
Pregnancy
Occluded central veins
Active infection
Coronary anatomy at risk of compression at the time of implant
PI  pulmonary insufficiency; RV  right ventricle; RVOT  right ventricular outflow tract;
VO2max oxygen consumption at peak exercise.in). Patients were excluded from imaging if they had
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441revious implants that would interfere with image acquisi-
ion (i.e., Harrington rods, pulmonary artery stents).
entricular volumes and function assessment. Electro-
ardiogram-gated steady state free precession cine magnetic
esonance images of the heart were acquired in the short-
xis, vertical long-axis, 4-chamber, and RVOT planes
overing both ventricles in entirety. Assessment of left
entricular (LV) and RV volumes was performed manually
t end-diastole and systole (Mass Analysis and CV Flow,
edis Medical Imaging Systems, Leiden, the Netherlands).
ardiac output was obtained by multiplying the heart rate
nd effective forward flow through ascending aorta for LV
utput and main pulmonary artery for RV output. In the
resence of PR, RV stroke volume was calculated as a
ifference between RV forward blood flow volume and PR
olume.
low assessment. Phase-contrast velocity mapping of the
ows was performed parallel to the RVOTs and LV outflow
racts with PR fraction calculated as percent backward flow
ver forward flow.
ardiac catheterization protocol. All procedures were per-
ormed under general anesthesia. Coronary angiography
as obtained in all, and simultaneous balloon inflation in
he RVOT was performed in those thought potentially at
isk for coronary compression during valve implantation.
he conduct of the catheterization procedure was similar to
hat outlined previously (13,14).
tatistical analysis. Data are described as mean  SD and
edian with minimum and maximum values as appro-
riate. A normalized z-score was calculated for dimen-
ional variables on the basis of body surface area. Free-
om from reintervention and surgery was depicted with
aplan-Meier nonparametric estimates. Paired t tests
ere performed to compare echocardiographic and an-
Figure 1. Type of Lesion
A mean right ventricular outﬂow tract (RVOT) gradient of 40 mm Hg was
used as a cutoff for pulmonary stenosis—grade 3 or more for pulmonary
insufﬁciency.iographic measurements, exercise test results, and MRI (nvestigations before and after PPVI. Changes over time
n echocardiographic parameters were assessed in linear
egression models and adjusted for repeated measures
hough an autoregressive covariance structure with the
chocardiographic parameter as the dependent variable
nd the time since implantation as the independent
ariable. For the ventilatory response to carbon dioxide
roduction (VE/VCO2) parameter, the PPVI cohort
ere matched to normal adolescents with structurally
ormal hearts, undergoing evaluation for a family history
f a cardiac disorder, palpitations, chest pain, or syncope.
or each implant, 2 sex- and age-matched control subjects
ere selected. The VE/VCO2 parameters between groups
control subjects and patients) were compared with linear
egression models adjusted for matching through a com-
ound symmetry covariance structure. A p value of 0.05
as considered statistically significant. Statistical analysis
as performed with SAS Statistical Software version 9.1
SAS Institute, Cary, North Carolina).
esults
atient characteristics. Between October 2005 and Decem-
er 2008, a PPVI was attempted in 28 adolescents (16 male
ubjects; median age 14.9 years, age range 10.9 to 19 years;
eight 57.7 kg, range 40 to 90.6 kg) (Table 2). Most (n 
6; 57%) had a variant of Fallot’s tetralogy with pulmonary
tresia. Eleven of the group (39%) had Hancock RV to
ulmonary artery valved conduits (Medtronic, Minneapolis,
innesota) or Hancock valves (n  6; 21%) placed at
urgery, whereas 7 (25%) had pulmonary (n  5) or aortic
n  2) homografts. Two had Symbion (Symbion, Salt
ake City, Utah) valves, 1 of which was stented, and the
ther was balloon-dilated at an earlier procedure, and an
dditional 2 had their RVOTs stented after a Réparation à
’Etage Ventriculair procedure (15). Three (30%) of the 10
ancock conduits, 2 (33%) of the 6 Hancock valves, and 2
28%) of the 7 homografts were also stented at an earlier
rocedure to address stenosis. Sixty-four percent of the
roup had 2 surgical procedures, and 61% had 2
nterventional procedures before the PPVI. Age at primary
epair was 1.7  1.9 years, with 10 (36%) having initial
alliation in the form of a Blalock-Taussig shunt. The time
rom last intervention to PPVI was 5.2  2.8 years (range
8 days to 9 years). Seventeen (61%) had a mixed lesion, 9
32%) exclusively stenosis, and 2 (7%) isolated pulmonary
nsufficiency (Fig. 1).
mmediate results. The Melody (Medtronic) valve was suc-
essfully implanted in all, with a femoral venous approach in
3 and a transjugular approach in 5. The median procedure
ime was 150 min (range 65 to 309 min), and fluoroscopy
ime was 34 min (range 5 to 107 min). Additional proce-
ures performed included: pre-PPVI RVOT stenting in 7
25%), right pulmonary artery stent dilation in 2 (7%), and
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442n inferior caval vein stent dilation in 1 child (3%). After
mplantation, the valve appeared abutted to the sternum in
3% (12 of 28) and away from the sternum in 39% (11 of
8) of the cohort. In 5 (18%), the valve was away from the
ternum but in a horizontal position. Acute complications
ncluded 1 balloon rupture during conduit pre-dilation
ithout vessel injury and 1 conduit disruption after balloon
ilation. In the latter, bleeding was contained without
ffecting hemodynamic status, the tear sealed by the valve
mplant. There was 1 local vascular complication (arte-
ial aneurysm), which resolved with ultrasound guided
Table 2. Group Characteristics
Children 28
Male/female 16/12
Primary diagnosis
PA/VSD 9 (32)
TOF 7 (25)
PAT 5 (18)
DORV, TGA/PS 2 (7)
AI 2 (7)
ccTGA/PS 2 (7)
AoA/VSD 1 (4)
Primary repair
RV–PA conduit 17 (61)
TAP 6 (21)
Ross 1 (4)
Ross-Konno 1 (4)
Yasui 1 (4)
REV 2 (6)
Age at primary repair (yrs) 1.7 1.9
Previous palliation:
Left or right BT shunt 10 (36)
Previous surgeries 2.25 0.5
Previous interventions 1.5 0.4
Time from last intervention to PPVI (yrs) 5.2 2.8
Age at implantation (yrs) 14.9 2.6
Weight (kg) 57.7 12.7
RVOT morphology
Hancock valve 6 (21)
Hancock conduit 10 (36)
Homograft 7 (25)
Other 5 (18)
Procedure time (min) 150 (65–309)
Fluoroscopy time (min) 34 (5–107)
Additional procedures at time of PPVI RVOT stent (7)
RPA stent dilation (2)
Data presented as n, n (%), mean SD, or n (range).
AI  aortic insufficiency; AoA  aortic atresia; BT  Blalock-Taussig; ccTGA  congenitally
corrected transpositionof great arteries;DORVdoubleoutlet right ventricle; IVC inferior vena
cava; PA/VSD  pulmonary atresia/ventricular septal defect; PAT  persistent arterial trunk;
PPVI  percutaneous pulmonary valve implantation; PR  pulmonary regurgitation; PS  pul-
monary stenosis; REV Réparation à l’Etage Ventriculair; RPA right pulmonary artery; RVOT
right ventricular outflow tract; RV–PA right ventricle to pulmonary artery; TAP transannular
patch; TOF tetralogy of Fallot.ompression.verall results. At catheterization, the RVOT gradient, RV
ystolic pressure, and systolic-pressure/systemic-pressure ra-
io fell significantly, whereas aortic systolic pressure in-
reased (Table 3, Fig. 2). The entire cohort demonstrated,
ngiographically, a significant reduction in PR associated
ith an increase in pulmonary artery diastolic pressure.
cute results by dominant lesion. There were no significant
ifferences between the stenotic and mixed lesion groups in
he degree of RV-to-pulmonary artery gradient and RV
ystolic pressure reduction. Improvement in PR was similar
n both lesion types. The sample size was too small (n  2)
o make statistically significant conclusions in the purely
egurgitant group.
chocardiographic observations. Echocardiography per-
ormed within the first 24 h after valve implantation,
ompared with studies obtained immediately before cathe-
erization (Table 4), noted that the RV pressure significantly
ecreased, the RVOT gradient fell, and RV/aortic pressure
atio decreased. Nineteen (68%) of 28 had moderate-to-
evere PR (grade 3) before implant, and 1 month later, 19
80%) had no detectable PR (p  0.001) (Fig. 3).
RI. Cardiac MRI was performed in 14 of the cohort (50%)
t a median 183 days (range 1 to 449 days) after implanta-
ion (Table 5, Fig. 4). In 5, MRI was not possible due to an
rtifact from the previously stented RVOT. Six of the
ohort did not have a cardiac MRI before the procedure,
nd 3 moved, and follow-up MRI was not available. Eleven
ad cardiac MRI performed before and after PPVI, whereas
were awaiting follow-up studies at the time of this report.
n 1, PR fraction was not calculated.
There was a significant decrease in right ventricular
nd-diastolic volume (RVEDV) and RV end-systolic vol-
me with an improvement in RV cardiac output and
ffective stroke volume, indicating an improvement in RV
ystolic function; however, there was no significant change
n RV ejection fraction (EF). Sixty-four percent of the
ohort (7 of 11) had a PR fraction 20% (moderate or
evere PR) before implant and a significant reduction in the
Table 3. Catheterization Data (n  28)
Before PPVI After PPVI p Value
RV-PA gradient (mm Hg) 36 15 12 7 0.001
RVSp (mm Hg) 61 16 41 11 0.001
RVDp (mm Hg) 11 5 10 4 0.04
MPAPs (mm Hg) 26 8 30 9 0.02
MPAPd (mm Hg) 11 4 15 5 0.003
AoPs (mm Hg) 86 10 94 11 0.001
AoPd (mm Hg) 56 7 61 8 0.001
RV/Ao () 70 16 44 11 0.001
AoPs aortic pressure systolic; AoPd aortic pressure diastolic; AoPm aortic pressure mean;
MPAPdmain pulmonary artery pressure (diastolic); MPAPmmain pulmonary artery pressure
(mean); MPAPs  main pulmonary artery pressure (systolic); RVSp  right ventricular systolic
pressure; RVDp right ventricular diastolic pressure; RV/Ao right ventricular to aortic pressureratio; other abbreviations as in Table 2.
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443R fraction after implant. Five remained with detectable
R, of which 80% (4 of 5) had RVOT reconstruction with
ancock valve or conduit. Analysis of LV systolic indexes
ocumented a significant increase in left ventricular end-
iastolic volume (LVEDV), LV stroke volume, and LV
ardiac output but no change in LVEF. The ratio of
VEDV/LVEDV improved.
xercise capacity. Twenty-four of the group (86%) under-
ent cardiopulmonary exercise testing before implantation,
nd 19 underwent cardiopulmonary exercise testing after
median 6 months; range 1 to 26 months) implantation
Table 6). There was a significant improvement in oxygen
Figure 2. Catheterization Hemodynamic Data Before and After PPVI
Plots (bold lines  mean; red boxes  SD; upper and lower limits). (A) Rig
(C) PA systolic pressure; and (D) aorta systolic pressure before and after percu
Table 4. Follow-Up Echocardiographic Assessment
Before PPVI After PPVI 1 Month 3 M
RV–PA gradient (mm Hg) 67 23 41 16 36 11 3
RVSp (mm Hg) 78 22 58 17 56 8 5
RV/Ao ratio (%) 75 16 54 13 52 7 5
Patients (n) 28 24 24Abbreviations as in Table 3.onsumption at peak exercise and workload, with no signif-
cant change in anaerobic threshold. The VE/VCO2 im-
roved; however, a normal level (31  5) was not achieved,
here there remained a significant difference between
atched control subjects and the cohort after the implant.
linical follow-up. Follow-up ranged from 0 to 37 months
median 27.6 months). There was no mortality, and free-
om from reoperation was 91%, 83%, and 83% at 12, 24,
nd 36 months, respectively (Fig. 5). In 1 child, the implant
as positioned within a bare-metal stent, placed to reinforce
he conduit that abutted the sternum. Compression, stent
racture (both bare-metal and Melody valve), and recurrent
tricle (RV) systolic pressure; (B) RV to pulmonary artery (PA) gradient;
s pulmonary valve implantation (PPVI).
s 6 Months 12 Months 24 Months 36 Months p Value
32 12 32 11 36 16 31 5 0.001
54 14 53 12 56 13 54 11 0.001
50 13 48 9 50 9 44 7 0.001
21 16 13 3ht venonth
4 11
8 19
3 17
21
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444tenosis were noted 3 months after the procedure. A small
omponent of the bare-metal stent embolized to the left
ulmonary artery without obstruction, whereas the Melody
alve remained competent; the child subsequently under-
ent elective surgical repair. A second child, after repair of
persistent arterial trunk had valve implantation due to
onduit stenosis and RV hypertension. The child subse-
Figure 3. Pulmonary Valve Competence at Follow-Up by Echocardiography
PPVI  percutaneous pulmonary valve implantation.
Table 5. MRI Volumetric Data (n  14)
Before PPVI After PPVI p Value
RVEDV (ml/m2) 149 49 114 35 0.005
RVESV (ml/m2) 85 48 63 29 0.005
RV effSV (ml/m2) 44 12 48 8 0.04
RVEF (%) 42 15 46 13 0.43
RV CO (l/min) 2.7 0.5 3.4 0.8 0.04
LVEDV (ml/m2) 90 19 97 20 0.007
LVESV 37 10 39 11 0.6
LV effSV (ml/m2) 50 13 57 14 0.02
LVEF (%) 56 9 60 7 0.24
LV CO 2.7 0.6 3.2 0.6 0.02
RV/LVEDV 1.75 0.5 1.24 0.27 0.001
PR (%) 24 10 7 7 0.0001
effSV effective forward flow stroke volume; LV CO left ventricular cardiac output; LVEDV
left ventricular end-diastolic volume; LVEF left ventricle ejection fraction; LVESV left ventric-
ular end-systolic volume; LVSV  left ventricular stroke volume; MRI  magnetic resonance
image; RVEDV right ventricular end-diastolic volume; RV CO right ventricular cardiac output;
RVEF right ventricle ejection fraction; RVESV right ventricular end-systolic volume; RVSVsright ventricular stroke volume; other abbreviations as in Table 2.uently underwent stenting of the branch pulmonary
rteries; however, they remained obstructive, and additional
alloon dilation did not improve the hemodynamic status
RV hypertension). As a result, the child underwent conduit
eplacement with bilateral pulmonary arterioplasties. There
ere no additional device-related complications noted in
ollow-up.
Freedom from transcatheter reintervention was 91%,
0%, and 80%, at 12, 24, and 36 months, respectively (Fig.
). Balloon dilation of the implant (n  5) was performed
n average of 14.5  9 months (range 3.9 to 23.7 months)
fter the index procedure. Indications for intervention
ncluded RV-to-pulmonary artery gradient of 60 mm Hg
nd/or an elevated RV systolic pressure/aortic ratio (0.7)
y echocardiography. The etiology of the recurrent obstruc-
ion was most often due to initial underdeployment. At
atheterization the RV-to-pulmonary artery gradient was
0  21 mm Hg, and RV systolic pressure/aortic ratio was
2  21%. After balloon dilation, the gradient fell to 28 
1 mm Hg (p  0.001), and RV systolic/aortic pressure
atio was 62  24% (p  0.01). The incidence of stent
racture was 10.7% (n  3), from a review of digital
adiographic images an average of 7.5 months (range: 1 day
o 2.8 years) after implantation. None of the 5 catheter-
eintervened patients had stent fractures.
chocardiographic follow-up. Median follow-up was 27.6
onths, with serial studies available for review: 21 (75%)tudied at 6 months after the index procedure, 16 (57%)
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445tudied at 24 months, and 3 (11%) studied at 36 months
fter the procedure. Reductions in RV-to-pulmonary artery
radient, RV systolic pressure, and RV/systemic pressure
atio (Table 4) were preserved throughout the follow-up. At
4 months, only 1 child had moderate PI (grade 3), whereas
2% had no PR, and 31% had trivial PR (Fig. 3). The RV
Figure 4. MRI Ventricular Volume Parameters Before and After Pulmonary
Plots (bold lines  mean; red boxes  SD; upper and lower limits). (A) Rig
put (CO); (C) left ventricular end-diastolic volume (LVEDV); and (D) left ventricu
Table 6. Cardiopulmonary Exercise Test
Before PPVI
(n  24)
After PPVI
(n  14) p Value
Peak VO2 (ml/kg/min) 24 5 28 4 0.0001
VO2 AT (ml/kg/min) 18 3 20 3 0.07
% predicted VO2 55 12 63 11 0.0002
VE/VCO2 39 5 36 5 0.003
Workload (W) 86 15 99 25 0.003
Peak HR (beats/min) 167 24 171 21 0.40
RR 51 11 55 8 0.13
RER 1.13 0.09 1.19 0.09 0.20
HR heart rate; RER respiratory exchange ratio; RR respiratory rate; VE/VCO2 ventilatory
response to carbondioxideproduction; VO2oxygenconsumption; VO2AToxygenconsump-ftion at anaerobic threshold.nd-diastolic dimensions (expressed as z-scores) were im-
roved on the 6-month follow-up study (before PPVI: 2.8
range 0.0 to 5.9] to 1.3 [range 2.5 to 5.3], p  0.001)
eflecting RV reverse remodeling.
iscussion
e report our experience with 28 adolescents who under-
ent percutaneous pulmonary valve implantation. This is
he largest and longest single-centre experience described in
orth America to date and constitutes the youngest group
eported. Unique to this report is the outcomes in a pediatric
opulation with very dilated RVs (RVEDV 140 ml/m2).
e have shown that PPVI is an effective and safe treatment
or RVOT dysfunction, which can be achieved with mini-
al complications and no mortality. Additionally in this
tudy, most patients (57%, 16 of 28) had the Melody valve
mplanted within a bioprosthetic valve, in contrast to the
revious reports (13). In this regard, the incidence of stent
Implantation
tricular end-diastolic volume (RVEDV); (B) right ventricular (RV) cardiac out-
V) CO. MRI  magnetic resonance image.Valve
ht venracture (10%) as compared with the previously reported
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4460% (16–18) might be explained by better stability within
he valve-in-valve implant.
There was a significant decrease, acutely, in RV hyper-
ension, relief of outflow obstruction, and near-elimination
f regurgitation, in both stenotic and mixed lesion groups.
he longevity of the hemodynamic improvements is critical
o determine whether this therapy will have an impact on
linical course. In this regard, follow-up echocardiographic
ata demonstrated sustained reduction in RV-to-pulmonary
rtery gradients and RV pressures in those with pressure-
verloaded and/or volume-loaded ventricles. Furthermore,
e observed a sustained decrease in RVED dimensions
hroughout the follow-up.
The RVEDV and right ventricular end-systolic volume
mproved significantly; however, they did not normalize to
he same degree as found in the patients after surgical
VOT reconstruction (19). As such, surgical populations
end to address predominantly volume-overloaded ventricles
ue to PR, whereas our cohort had a predominantly mixed
esion (both pulmonary stenosis and PR). Furthermore, the
RI follow-up in our study, performed at 6 months after
PVI, assessed the ventricle at a time when complete
emodeling might not be fully manifest. In contrast to other
PVI studies (14), this young population demonstrated a
ignificant reduction (24% change) in RV volumes, in very
arge chambers (on average 50 ml/m2 larger then reported in
rior PPVI studies), underscoring that significant reverse
emodeling can be obtained if performed early in the clinical
ourse (19). Additionally noted was an improvement in RV
ardiac output without a change in RVEF. This is consis-
ent with earlier studies in PPVI populations where im-
rovement in RVEF was seen only in the patients with
rimary RV obstruction and minimal PR (13,20,21) but not
Figure 5. Freedom From Reoperation or Reintervention
Freedom from reoperation (solid red line) or reintervention (dashed black
line). PVR  pulmonary valve replacement.n the PR group or combined cohort of mixed lesions dstenosis and regurgitation). Similar surgical series have also
oted that valve implantation causes little improvement in
VEF (22–26). The effects of severe PR on RV function in
atients with RVOT obstruction (by cardiac MRI) also
esult in an elevated RVEDV and reduced RVEF (27), with
VEF lower in patients with both RV pressure and volume
verload when compared with pressure-overloaded RV
lone (27). These observations reflect interplay among
hronic volume overload, myocardial stretch, decreased
ontractile reserve, and fibrosis.
The RVEF on cardiac MRI study in our population
evealed no significant change in EF with an increase in RV
troke volume, which reflected a reduction in PR. The
ffective stroke volume (stroke volume minus pulmonary
egurgitant volume) improvement reflected the improve-
ent in RV cardiac output and therefore overall RV
erformance, not requiring an increase in EF in this young
opulation with predominantly regurgitant or mixed lesions.
After valve implantation and relief of RVOT obstruction,
here was a concomitant improvement in LV performance:
VEDV, LV stroke volume, and LV cardiac output signif-
cantly increased. These improvements in function corre-
ated with improvements in maximal exercise capacity, as
reviously noted in other PPVI series (13,21), with excep-
ion of patients with volume-overloaded ventricles (21).
n contrast, surgical series show minimal improvements
24,28) or no improvement (19) in exercise capacity. We
ostulate that the improvement in maximal oxygen con-
umption in our population is a consequence of increased
V size due to decreased RV volumes and improvement in
V cardiac output after relief of RV regurgitation. This
ould be manifest due to the shorter exposure of the
entricle to altered loading conditions. Furthermore, this
bservation suggests that earlier intervention on patients
ith conduit dysfunction can normalize ventricular function
nd exercise capacity.
The improvement in VE/VCO2 reflects improved pul-
onary perfusion due to an increase in RV forward flow. As
predictor of mortality and morbidity in patients with
ongenital heart disease (29,30), these findings are most
ncouraging. Although we observed an improvement in
E/VCO2, when compared with age- and sex-matched
ontrol subjects, the improvement after 6 months was not
nto the normal range. The question of whether further
mprovement in VE/VCO2 is possible will require longer-
erm study.
It has been suggested in previous reports that the increase
n LVEDV and reduction in RVEDV, as noted in this
tudy after implantation, leads to clinical improvement
elated to improved diastolic chamber interactions (31), an
ncrease in LV preload, increased stroke volume, and
ubsequently cardiac output. Furthermore, abnormalities of
V diastolic function have been reported as important
eterminants of exercise intolerance (32). Intervention in
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447his age group demonstrated an improvement of LV indexes
nd exercise tolerance, reflected by improvements in the
VEDV/LVEDV ratio after implantation (1.75 to 1.25,
ormal 1.15), reflecting a shift toward normalization in
entricular interaction.
tudy limitations. Although we have reported immediate
enefits of PPVI with early-term follow-up, longer-term
tudies will be needed to determine longevity of the percu-
aneous valve compared with surgical interventions. In our
ohort, there was no mortality, and the rate of re-
ntervention and reoperation was minimal despite the im-
act of a learning curve. The subjects suffered from complex
esions with multiple previous operations on the RVOT,
eterogeneous in terms of diagnosis and RVOT morphol-
gies. Most were younger than 20 years of age (median age
4.9 years) and had very dilated RVs, making the cohort
omogenous with regard to age. A comparison with groups
f children with less-dilated RVs would be needed to
valuate the potential for RV reverse remodeling and
ustainability of symptomatic relief. Cardiopulmonary exer-
ise testing could not be obtained in the entire cohort.
ardiac MRI was not performed in all before PPVI. In
hose patients with previous RVOT stent, MRI was not
ptimal due to image distortion. Echocardiographic indexes
f diastolic function were not obtained, making more
etailed assessment unavailable.
onclusions
n summary, these data describe a unique population of
dolescents with significantly enlarged RV chambers, poor
xercise performance, and dysfunctional conduits who un-
erwent PPVI. The RV chamber dimensions decreased,
xercise performance improved, and LV chamber dimen-
ions and cardiac output improved. This unique series of
bservations supports earlier studies, which suggest that
egurgitation and/or outflow tract obstruction should be
ddressed early, with excellent immediate and early-term
linical and hemodynamic outcomes.
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